Africa and Middle East Cardiovascular Epidemiological Study
NCT01243138
Last updated date
ABOUT THIS STUDY
This is a cross-sectional, epidemiological study to determine the prevalence of
cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and
hypertension in patients attending General Practice clinics in the Africa and Middle East
region. A total of 4300 patients will be evaluated. In patients who are found to have
previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or
hypertension, the level of control of their respective conditions will also be evaluated.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Obesity, Smoking, Dyslipidemia, Diabetes Mellitus, Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Adult aged 18 or above
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Pregnant women and/or lactating mothers
- Subjects presenting with any life threatening disease/condition
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Obesity, Smoking, Dyslipidemia, Diabetes Mellitus, HypertensionAfrica and Middle East Cardiovascular Epidemiological Study
NCT01243138
- Alger,
- Bejaja,
- Djelfa,
- Laghouat,
- M'Sila,
- Relizane,
- Saida,
- Tebessa,
- Tlemcen,
- Yaounde, Cite Verte
- Douala, Deido
- Bafoussam,
- Mbandjock,
- Njombe,
- Soa,
- Alexandria,
- Cairo,
- Shiben Al Kom,
- Tanta,
- Accra,
- Jachie-Ashanti,
- Kumasi,
- Sogakope V/R,
- Takoradi,
- Amman,
- Irbid,
- Salt,
- Chongoria,
- Nairobi,
- Adailiya,
- Fahaheel,
- Kuwait,
- Mishref,
- Qadesya,
- Yarmouk,
- Beirut,
- Jbeil, Lebanon,
- Jounieh,
- Tripoli,
- Abuja, FCT,
- Abuja, Garki,
- Calabar,
- Enugu,
- Keffi, Nassarawa,
- Dammam,
- Jeddah 21573,
- Jeddah,
- Makkah,
- Riyadh,
- Riyadh,
- Yanbu,
- Dakar, Nabil Choucair
- Dakar, Ouakam
- Kebemer,
- Kedoungou,
- Saint Louis,
- Ziguinchor,
- Halfway House, Gauteng
- Sydenham, Durban, Kwazulu-natal
- Mokopane, Limpopo
- Sheshego, Limpopo
- Mamelodi East, Pretoria
- Kwa-Zulu Natal,
- Rondebosch,
- Ariana,
- Bouficha,
- Messaadine,
- Sfax,
- Tunis,
- Zaghouan,
- Abu Dhabi,
- Al Ain,
- Dubai,
- Ras Al Khaima,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title | Africa and Middle East Cardiovascular Epidemiological Study | |||
| Official Title | Prevalence of Cardiovascular Risk Factors in Patients Attending General Practice Clinics in Selected Countries in the Africa and The Middle East Region | |||
| Brief Summary | This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics in the Africa and Middle East region. A total of 4300 patients will be evaluated. In patients who are found to have previously been diagnosed with cardiovascular (CV) risk factors such as dyslipidemia or hypertension, the level of control of their respective conditions will also be evaluated. | |||
| Detailed Description | This is a cross-sectional, epidemiological study. In the course of this study, 4,300 persons from general practice, and other non specialist clinics of selected countries of the Africa and Middle East region, will be evaluated for the presence of cardiovascular (CV) risk factors such as obesity, smoking, dyslipidaemia, diabetes mellitus and hypertension. The degree of control of hypertension and dyslipidaemia in those previously diagnosed with these conditions will also be assessed. All medications used for CV risk factor control will also be ascertained. Patient evaluation will be done by physicians in charge of the selected clinics (who will be trained for case report forms completion) over one visit, through history taking, clinical examination as well as laboratory investigations. Every fifth patient seen on a particular day, fulfilling the inclusion and exclusion criteria would be included in the study. | |||
| Study Type | Observational | |||
| Study Design | Observational Model: Other Time Perspective: Cross-Sectional | |||
| Target Follow-Up Duration | Not Provided | |||
| Biospecimen | Retention: None Retained Description: Whole Blood | |||
| Sampling Method | Probability Sample | |||
| Study Population | Subject selection would be from clinics in a primary care setting | |||
| Condition |
| |||
| Intervention | Not Provided | |||
| Study Groups/Cohorts | Not Provided | |||
| Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status | Completed | |||
| Actual Enrollment | 4386 | |||
| Original Estimated Enrollment | 4300 | |||
| Actual Study Completion Date | April 2012 | |||
| Actual Primary Completion Date | April 2012 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender |
| |||
| Ages | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers | Yes | |||
| Contacts | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries | Algeria, Cameroon, Egypt, Ghana, Jordan, Kenya, Kuwait, Lebanon, Nigeria, Saudi Arabia, Senegal, South Africa, Tunisia, United Arab Emirates | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number | NCT01243138 | |||
| Other Study ID Numbers | A2581186 | |||
| Has Data Monitoring Committee | No | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement | Not Provided | |||
| Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
| Study Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
| Collaborators | Not Provided | |||
| Investigators |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2021 | |||